


Moldova

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline		2009		2012		2015		2018
International units	Factor VIII	0.13	A	0.23	_	0.11	A	1.12
per capita	Factor IX	0.00		0.00		0.00	A	0.06
Organisation	Comprehensive Care Centres (CCC's)	No		No		No		No
of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group							
	Number of groups in decision-making on haemophilia care	0		0		0		0
	Number of groups choosing haemophilia treatment products	0		0		0		0
	National Tender for procurement of factor concentrates							
Treatment	Home Treatment	No		No		No		
regimens	% of people with haemophilia using home treatment	<10%		<10%		<10%		
	Treatment delivered to the patient's home							
	Prophylaxis treatment availability	No		No		No		No
	Children currently on prophy (%)	0		0		0		0
	Adults currently on prophy (%)	0		0		0		0
	Access to ITI (% of people with inhibitors)	0		0		0		0
Access to	Emergency medicine and acute surgery							
specialist services	Paediatrics							
	Infectious disease specialists (especially HIV)							
	Hepatology							
	Rheumatology							
	Orthopaedics							
	Physiotherapy							
	Dentistry							
	Obstetrics and Gynaecology							
	Genetics							
	Social and psychological support							
	Pain management							
	General surgery							
	Urology							
Share of Expected	Haemophilia A	78%				70%	_	78%
Bleeding Disorder	Haemophilia B	15%	A	16%	_	20%	_	23%
Prevalence	von Willebrand Disease	0%	A	0%	A	0%	_	0%
Haemophilia	Pasma-derived factor concentrate	Rarely		Rarely		Rarely		Rarely
replacement	Recombinant factor concentrate	Rarely		Rarely	_	Never	_	Rarely
therapy	Plasma	Never		Never		Never		Never
	Cryoprecipitate	Rarely		Rarely		Rarely		Rarely
VWD replacement	Plasma-derived factor concentrate	,		,		,		,
therapy	DDAVP							
	Plasma							